Latest research suggests that the pharmacokinetics of technosphere insulin works the same in children living with type 1 diabetes as it does in adults with the same condition.
In this first-of-a-kind study, a team of scientists have analysed how technosphere insulin – an inhaled dry powder ultra-rapid-acting insulin – impacts children living with type 1 diabetes.
Pharmacokinetics of technosphere insulin and its effect on circulating glucose concentrations were evaluated in a single-arm study that enrolled 27 children aged between eight and 17 years old with type 1 diabetes for more than one year.
All of the children enrolled in the study were also on a stable multiple daily insulin injection regimen and meet pre-defined pulmonary function testing criteria.
To assess pharmacokinetics, the children received an individualised single preprandial dose of technosphere insulin (4–12 U, in 4-U increments) via oral inhalation, based on their usual mealtime subcutaneously injected rapid-acting insulin dose and meal content. Serum insulin and blood glucose were also measured at 30 to 250 min relative to dosing.
The findings state: “Serum insulin rapidly increased post-dose and returned to baseline by 120 min.
“Mean serum insulin Cmax (maximum concentration) was 77.3, 119.15, and 207.7 µU/mL for doses of 4, 8, and 12 U, respectively.
“Tmax occurred at 10.5, 13.9, and 14.6 min post-dose for 4, 8, and 12 U. Glucose lowering 30–60 min post-dose was consistent with the pharmacokinetics profile.”
To read the study, click here.
Photo by Jerry Wang on Unsplash
Register an account or login to comment
Diabetes UK issues latest guidance on coronavirus
People with diabetes urged to be ‘particularly stringent’ amid COVID-19 pandemic
NHS Drug Tariff approval for FreeStyle Libre System
Updated metformin and B12 guidance published
Criticism over Eatwell Plate amid calls for low carb approach
Type 1 man no longer requires insulin
Man commended for living with diabetes for 80 years
Warning over Lucozade sugar reduction
FreeStyle® Libre 2 includes optional real-time alarms
Novo Nordisk UK launches Ozempic® (semaglutide)
DKA expert features in latest Diabetes Times podcast
Type 2 diabetes remission can be achieved by following a low-carb diet, evidence reveals
Time-action profile of technosphere insulin in children with type 1 diabetes identified in first-of-a-kind study
Revised chronic kidney disease guideline published
Study sheds light on incidence of diabetes following hospital admission for COVID-19 and pneumonia
Weight loss surgery now less common in people with type 2 diabetes, academics say
Agenda reveals hot topics to be explored at national conference on diabetes footcare
Brits living with diabetes feel stigma and bias impact their ability to manage their condition
UK study shows increased cancer mortality in people with type 2 diabetes
New diabetes webinar series to start with session on continuous glucose monitoring
Advanced Diabetes Podiatrist
Paediatric Diabetes Dietitian
Diabetes Support Nurse
Diabetes Specialist Nurse
Band 7 Diabetes Specialist Nurse
Inpatient Diabetes Specialist Nurse
Consultant in Diabetes
Consultant in Diabetes and Endocrinology
Diabetes Specialist Nurse
Diabetes Inpatient Specialist Nurse
This website is certified by Health On the Net Foundation. Click to verify.
The Diabetes Times © 2023


By admin

Leave a Reply

Your email address will not be published. Required fields are marked *